Phathom Pharmaceuticals (PHAT) Non Operating Income (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Non Operating Income of -$13.6 million for Q2 2026, up 14.28% year-over-year from -$11.9 million in Q2 2025, and up 8.56% quarter-over-quarter from -$14.9 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Non Operating Income (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Non Operating Income for 9 consecutive years, with -$13.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non Operating Income rose 14.28% year-over-year to -$13.6 million; the TTM figure through Jun 2026 stood at -$58.4 million (up 4.45% YoY), while the FY2025 annual figure was -$61.3 million, down 7.74% from the prior year.
- Non Operating Income advanced to -$13.6 million in Q2 2026 per PHAT's latest filing, from -$14.9 million in the prior quarter.
- Across five years, Non Operating Income topped out at -$2.8 million in Q1 2022 and bottomed at -$15.9 million in Q2 2025.
- Historically, Non Operating Income has averaged -$11.5 million across 5 years, with a median of -$13.3 million in 2024.
- Annual changes were most pronounced in 2022 — Non Operating Income slumped 350.69% — and 2026, when it advanced 14.28%.
- Phathom Pharmaceuticals' Non Operating Income stood at -$8.4 million in 2022, then slipped by 15.35% to -$9.7 million in 2023, then sank by 55.07% to -$15.0 million in 2024, then declined by 1.24% to -$15.2 million in 2025, then increased by 10.53% to -$13.6 million in 2026.
- Business Quant data shows PHAT's Non Operating Income at -$13.6 million in Q2 2026, -$14.9 million in Q1 2026, and -$15.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | -13.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.62 Mn |
| Mar 31, 2026 | -14.89 Mn |
| Dec 31, 2025 | -15.22 Mn |
| Sep 30, 2025 | -14.70 Mn |
| Jun 30, 2025 | -15.89 Mn |
| Mar 31, 2025 | -15.45 Mn |
| Dec 31, 2024 | -15.03 Mn |
| Sep 30, 2024 | -14.78 Mn |
| Jun 30, 2024 | -14.15 Mn |
| Mar 31, 2024 | -12.90 Mn |
| Dec 31, 2023 | -9.70 Mn |
| Sep 30, 2023 | -7.58 Mn |
| Jun 30, 2023 | -9.26 Mn |
| Mar 31, 2023 | -7.74 Mn |
| Dec 31, 2022 | -8.41 Mn |
| Sep 30, 2022 | -8.56 Mn |
| Jun 30, 2022 | -5.56 Mn |
| Mar 31, 2022 | -2.76 Mn |
| Dec 31, 2021 | -2.79 Mn |
| Sep 30, 2021 | -3.53 Mn |